An Intravenous Ketamine Test as a Predictive Response Tool in Opioid-Exposed Patients with Persistent Pain

Journal of Pain and Symptom Management

Volumn 37, Issue 4, 2009, Pages 698-708

  Cohen, Steven P ^a,b   Wang, Shuxing ^c   Chen, Lucy ^c   Kurihara, Connie ^b   McKnight, Geselle ^b   Marcuson, Matthew ^b   Mao, Jianren ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dextromethorphan; infusion test; ketamine; N methyl d aspartate; opioid; predictive value; tolerance

Indexed keywords

DEXTROMETHORPHAN; KETAMINE; MIDAZOLAM; MORPHINE; OPIATE; PLACEBO;

ADULT; AGED; ANALGESIA; ANXIETY; ARTICLE; DIZZINESS; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG MEGADOSE; EUPHORIA; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; PAIN; PLACEBO EFFECT; PREDICTION; SEDATION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ANESTHETICS, DISSOCIATIVE; CHRONIC DISEASE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; PAIN; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 63249128251     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2008.03.018     Document Type: Article

References (48)

1. Ram S., Kumar S.K., and Clark G.T. Using oral medications, infusions and injections for differential diagnosis of orofacial pain. J Calif Dent Assoc 34 (2006) 645-654
2. Vickers E.R., and Cousins M.J. Neuropathic orofacial pain. Part 2-diagnostic procedures, treatment guidelines and case reports. Aust Endod J 26 (2000) 53-63
3. Arner S. Intravenous phentolamine test: diagnostic and prognostic use in reflex sympathetic dystrophy. Pain 46 (1991) 17-22
4. Galer B.S., Miller K.V., and Rowbotham M.C. Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. Neurology 43 (1993) 1233-1235
5. Woolf C.J., American College of Physicians, and American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140 (2004) 441-451
6. Dworkin R.H., Backonja M., Rowbotham M.C., et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60 (2003) 1524-1534
7. Gustorff B. Intravenous opioid testing in patients with chronic non-cancer pain. Eur J Pain (2005) 123-125
8. Attal N., Guirimand F., Brasseur L., et al. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology 58 (2002) 554-563
9. Saitoh Y., Hirano S., Kato A., et al. Motor cortex stimulation for deafferentation pain. Neurosurg Focus 11 (2001) E1
10. Canavero S., and Bonicalzi V. Extradural cortical stimulation for central pain. Acta Neurochir Suppl 97 (2007) 27-36
11. Cohen S.P., Verdolin M.H., Chang A.S., et al. The IV ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain 7 (2006) 391-398
12. Galer B.S., Harle J., and Rowbotham M.C. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage 12 (1996) 161-167
13. Trentin L., and Visentin M. The predictive lidocaine test in treatment of neuropathic pain. Minerva Anestesiol 66 (2000) 157-161
14. Cohen S.P., Chang A.S., Larkin T., and Mao J. The IV ketamine test: a predictive response tool for an oral dextromethorphan treatment regimen in neuropathic pain. Anesth Analg 99 (2004) 1753-1759
15. Muller W., Schneider E.M., and Stratz T. The classification of fibromyalgia syndrome. Rheumatol Int 27 (2007) 1005-1010
16. Salerno A., Thomas E., Olive P., et al. Motor cortical dysfunction disclosed by single and double magnetic stimulation in patients with fibromyalgia. Clin Neurophysiol 111 (2000) 994-1001
17. Graven-Nielsen T., Aspegren Kendall S., Henriksson K.G., et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 85 (2000) 483-491
18. Sorenson J., Bengtsson A., Ahlner J., et al. Fibromyalgia-are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 24 (1997) 1615-1621
19. Staud R., Vierck C.J., Cannon R.L., Mauderli M.P., and Price D.D. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91 (2001) 165-175
20. Parsons C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 429 (2001) 71-78
21. Hewitt D.J. N-methyl-D-aspartate-enhanced analgesia. Curr Pain Headache Rep 7 (2003) 43-47
22. Grass S., Hoffmann O., Xu X.J., and Wiesenfeld-Hallin Z. N-methyl-D-aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat. Acta Physiol Scand 158 (1996) 269-273
23. Plesan A., Hedman U., Xu X.J., and Wiesenfeld-Hallin Z. Comparison of ketamine and dextromethorphan in potentiating the antinociceptive effect of morphine in rats. Anesth Analg 86 (1998) 825-829
24. Elliott K., Hynansky A., and Inturrisi C.E. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 59 (1994) 361-368
25. Trujillo K.A., and Akil H. Inhibition of opiate tolerance by non-competitive n-methyl-d-aspartate receptor antagonists. Brain Res 633 (1994) 178-188
26. Caruso F.S. Morphidex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain. J Pain Symptom Manage 19 (2000) S31-S36
27. Chevlen E. Morphine with dextromethorphan: conversion from other opioid analgesics. J Pain Symptom Manage 19 (2000) S42-S49
28. Katz N.P. Morphidex (MS:DM) double-blind, multiple-dose studies in chronic pain patients. J Pain Symptom Manage 19 (2000) S37-S41
29. Galer B.S., Lee D., Ma T., Nagle B., and Schlagheck T.G. Morphidex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 115 (2005) 284-295
30. Dudgeon D.J., Bruera E., Gagnon B., et al. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage 33 (2007) 365-371
31. Panitch H.S., Thisted R.A., Smith R.A., et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 59 (2006) 780-787
32. Carlsson K.C., Hoem N.O., Moberg E.R., and Mathisen L.C. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 48 (2004) 328-336
33. Ben Abraham R., Marouani N., and Weinbroum A.A. Dextromethorphan mitigates phantom pain in cancer amputees. Ann Surg Oncol 10 (2003) 268-274
34. Sang C.N., Booher S., Gilron I., et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 96 (2002) 1053-1061
35. Heiskanen T., Hartel B., Dahl M.L., et al. Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 96 (2002) 261-267
36. Gilron I., Booher S.L., Rowan M.S., et al. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology 55 (2000) 964-971
37. Nelson K.A., Park K.M., Robinovitz E., et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 48 (1997) 1212-1218
38. McQuay H.J., Carroll D., Jadad A.R., et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 59 (1994) 127-133
39. Furuhashi-Yonaha A., Iida H., Asano T., et al. Short- and long-term efficacy of oral ketamine in eight chronic-pain patients. Can J Anaesth 49 (2002) 886-887
40. Haines D.R., and Gaines S.P. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 83 (1999) 283-287
41. Lauretti G.R., Lima I.C., Reis M.P., et al. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 90 (1999) 1528-1533
42. Mao J., Price D.D., Hayes R.L., et al. Intrathecal treatment with dextrorphan and ketamine potently reduce pain-related behaviors in a rat model of painful peripheral mononeuropathy. Brain Res 605 (1993) 163-168
43. Bernard S.A., and Bruera E. Drug interactions in palliative care. J Clin Oncol 18 (2000) 1780-1799
44. Bowdle T.A. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. Drug Saf 19 (1998) 173-189
45. Cohen S.P., Christo P.J., Wang S., et al. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med 33 3 (2008) 199-206
46. Bailey C.P., and Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5 (2005) 60-68
47. Ossipov M.H., Lai J., King T., et al. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 80 (2005) 319-324
48. Mercadente S., and Portenoy R.K. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 21 (2001) 144-150